1223 / 1578
Phase I study of alectinib in crizotinib-resistant ALK-positive NSCLC
Ou et al, Lancet Oncol 2014
„Good response but no cure“
Regular controls are necessary
to detect new metastasis
|
|
1223 / 1578
Phase I study of alectinib in crizotinib-resistant ALK-positive NSCLC
Ou et al, Lancet Oncol 2014
„Good response but no cure“
Regular controls are necessary
to detect new metastasis